PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 4, 2006New England Journal of Medicine5,918 citationsOpen Access

Ranibizumab for Neovascular Age-Related Macular Degeneration

View Full Paper
PRPhilip J. RosenfeldDBDavid M. BrownJHJeffrey S. Heier

Key Points

  • The aim is to evaluate the efficacy of intravitreal ranibizumab in preventing vision loss in patients with neovascular age-related macular degeneration.
  • Intravitreal administration of ranibizumab was conducted over a 2-year period.
  • Participants included those with minimally classic or occult choroidal neovascularization secondary to age-related macular degeneration.
  • The trial registration number is NCT00056836.
  • Ranibizumab treatment prevented vision loss and improved mean visual acuity over the 2-year period.
  • Low rates of serious adverse events were observed during the treatment.
  • Specific numerical data regarding event rates and effect sizes were not provided, but treatment efficacy was indicated.

Abstract

Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration. (ClinicalTrials.gov number, NCT00056836 ClinicalTrials.gov.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Rosenfeld et al. (2006) studied this question.

synapsesocial.com/papers/69d7e88c5c3030ff03d18222https://doi.org/10.1056/nejmoa054481
Ask AI
Helpful
Bookmark
Share
View Full Paper